简介编辑本段回目录
官方简介编辑本段回目录
Mr. Watkins joined Abbott in 1985 as Business Unit Director, Physicians Office Diagnostics, with responsibility for starting a business to commercialize rapid tests and small instrument-based testing systems for physicians’ offices. In 1988, Mr. Watkins was appointed Divisional Vice President, Pharmaceutical Products Division. In early 1993, he was named Divisional Vice President and Sector General Manager, Benchtop Systems, Abbott Diagnostics Division, with responsibility for worldwide design, development and manufacturing of small laboratory instrument systems and related reagents, and with supervisory responsibility for approximately 450 people. In 1994, Mr. Watkins was appointed Area Vice President, Asia/Pacific, Abbott Diagnostics Division, with responsibility for all activities of Abbott’s Diagnostics Division affiliates in Japan and Asia, including overall supervision of approximately 1300 employees. In this capacity, Mr. Watkins also served as President of Abbott’s Japanese subsidiary, which included diagnostics R&D and manufacturing operations. He was promoted to Corporate Vice President in 1996, and, in 1998, was named Vice President of Abbott HealthSystems, Abbott’s corporate marketing and distribution division. Later that year, Mr. Watkins was appointed President of TAP.
Mr. Watkins began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the U.S., Europe and Japan. Mr. Watkins holds a bachelor’s degree from the College of William and Mary, and a master’s degree in business administration from the University of Chicago Graduate School of Business. He is a member of the Board of Directors of the Lake Forest Hospital Foundation and Lake Forest Hospital, Lake Forest, Illinois. He also serves as a Trustee of the William and Mary Business School Foundation at the College of William and Mary, Williamsburg, Virginia.
2009年度TheStreet最佳生物技术公司CEO揭晓 编辑本段回目录
人类基因组科技公司（Human Genome Sciences Inc，HDSI）CEO Thomas Watkins荣获TheStreet评选出的09年度最佳生物技术公司CEO桂冠。
Watkins因HGSI的红斑狼疮治疗新药Benlysta（belimumab）研究取得巨大成功而捧走Swanson奖杯（以基因泰克公司首席CEO Robert Swanson名字命名）。2009年有关Benlysta的两项III期临床研究均获得肯定性结果，成为该公司成功的标志，也为该公司首个重磅级产品问世铺平了道路。如果明年Benlysta能够顺利获得FDA批准，将成为几十年来第一个上市的用于治疗红斑狼疮的新药，预计可达到20-30亿美元的销售量。
该公司也创造了本年度生物技术投资的神话，股票由年初的2美元左右到现在的近30美元。仅凭这点，Watkins就足以获得最佳CEO的殊荣。
值得一提的是，HGSI研发总监David Stump博士理应与Watkins共享这一殊荣。Stump博士及其科学家团队发现并开发了Benlysta，，特别是Benlysta临床研究方案的独特设计，在很大程度上确保临床研究的成功。自上世纪90年代后期基因组泡沫出现后，HGSI承受了巨大的压力，而Benlysta有望成为该公司首个重磅级药物，将为公司挽回名声，其中Stump博士功不可没。
因在本年度有出色表现而获得表彰的其它生物技术公司的CEO：
Dendreon公司CEO Mitch Gold：该公司5月份公布的前列腺癌疫苗Provenge的全部临床研究数据令人兴奋，被华尔街最为看好，股票飙升。
Targacept公司CEO Don deBethizy：该公司开发的抗抑郁新药TC-5214获得成功，并在最为合适的时机与阿斯利康达成交易，为公司及其股东带来丰厚利润。
Medivation公司CEO David Hung：可谓“交易”先生，10月份就抗前列腺新药与Astellas达成交易，而一年前将其老年性痴呆新药成功地转让给辉瑞。
Celgene公司CEO Sol Barer因带领公司共克时艰也受到表扬。
艰难的转型后岁月 编辑本段回目录
参考文献编辑本段回目录
http://www.hgsi.com/latest/h.-thomas-watkins-appointed-chief-executive-officer-of-human-genome-sci.html
